Status:

TERMINATED

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Chronic Myeloproliferative Disorders

Diamond-blackfan Anemia

Eligibility:

All Genders

Up to 45 years

Phase:

NA

Brief Summary

RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system f...

Detailed Description

OBJECTIVES: Primary * Determine the engraftment potential of umbilical cord blood (UCB) in patients with hematological cancers. * Determine the safety of UCB transplantation in these patients. Seco...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of 1 of the following:
  • Leukemia including, but not limited to, the following subtypes:
  • Chronic myelogenous leukemia
  • Acute myeloid leukemia (primary or secondary)
  • Acute lymphoblastic leukemia
  • Lymphoma
  • Myelodysplastic syndrome
  • Aplastic anemia
  • Fanconi's anemia
  • Diamond-Blackfan anemia
  • Inborn errors of metabolism (e.g., Hurler syndrome, Maroteaux-Lamy syndrome, myelodysplastic syndrome VI, metachromatic leukodystrophy, adrenoleukodystrophy, and globoid cell leukodystrophy)
  • Immune deficiency disorders
  • Patients must meet the eligibility requirements outlined in currently active treatment protocols of the University of Minnesota Bone Marrow Transplant Program
  • HLA-identical or 1, 2, or 3 antigen mismatched umbilical cord blood (UCB) donor with at least one DRB1 match available
  • Unrelated or related donor
  • UCB specimen must contain ≥ 2.0 x 10\^7 nucleated cells/kg patient body weight
  • PATIENT CHARACTERISTICS:
  • See Disease Characteristics
  • No active infection
  • No history of HIV infection
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • PRIOR CONCURRENT THERAPY:
  • Not specified

Exclusion

    Key Trial Info

    Start Date :

    October 1 1999

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2007

    Estimated Enrollment :

    43 Patients enrolled

    Trial Details

    Trial ID

    NCT00290628

    Start Date

    October 1 1999

    End Date

    April 1 2007

    Last Update

    November 29 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Minnesota Cancer Center

    Minneapolis, Minnesota, United States, 55455